These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1695)

  • 41. [Antihypertensive action of various talinolol dosages after four week's treatment in comparison with placebo].
    Weigmann I; Terhaag B; Wierich W; Herrmann WM
    Arzneimittelforschung; 1998 Mar; 48(3):240-4. PubMed ID: 9553680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cadiovascular effects of local timolol therapy (author's transl)].
    Flammer J; Barth D
    Klin Monbl Augenheilkd; 1980 Apr; 176(4):561-5. PubMed ID: 7421029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The management vf essential hypertension with once daily administration of timolol maleate and bendrofluazide.
    Deering RB; Fox AS; Ison LJ
    J Int Med Res; 1977; 5(2):114-9. PubMed ID: 326593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hypotensive effects of timolol in 86 patients (author's transl)].
    Lagrue G; Gumpelson A; Kazandjan M; Grillot A
    Sem Hop; 1978 Oct 8-15; 54(29-32):929-32. PubMed ID: 216083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of timolol and atenolol on benign essential tremor: placebo-controlled studies based on quantitative tremor recording.
    Dietrichson P; Espen E
    J Neurol Neurosurg Psychiatry; 1981 Aug; 44(8):677-83. PubMed ID: 7028921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once-daily dosing of timolol in hypertension: a controlled study.
    Edwards IR; Else O
    Eur J Clin Pharmacol; 1980 Apr; 17(4):239-41. PubMed ID: 6995126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1).
    Meekers J; Missotten A; Fagard R; Demuynck D; Harvengt C; Pas P; Billiet L; Amery A
    Arch Int Pharmacodyn Ther; 1975 Feb; 213(2):294-306. PubMed ID: 238480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical-pharmacological evaluation of a new beta blocker, GYKI-41099 (tobanum).
    Török E; Istvánffy M; Halmágyi M; Wagner M; Csukás M
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):200-7. PubMed ID: 6104634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy and tolerability of tertatolol in the treatment of mild to moderate arterial hypertension. Results of a French multicenter study with 2,338 patients treated over one year].
    Herpin D; Piron J; Bajou B; Lecasble M
    Ann Cardiol Angeiol (Paris); 1989 Oct; 38(8):503-7. PubMed ID: 2574560
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of systemic autonomic inhibition on the hemodynamic response to antihypertensive therapy with timolol.
    Simon G; Kiowski W; Julius S
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):507-10. PubMed ID: 528098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison between timolol maleate and alphamethyldopa in longterm treatment of essential hypertension (author's transl)].
    G Ital Cardiol; 1981; 11(12):2110-6. PubMed ID: 7346307
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical experience with carvedilol.
    Moser M
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S16-20. PubMed ID: 8098064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carvedilol for systemic hypertension.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S113-8. PubMed ID: 2454356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antihypertensive action of drug combination: Timolol, hydralazine, hydrochlorothiazide and triamterene.
    Pörsti P; Jalonen K; Ryysy L; Toivonen T; Viherkoski M
    Ann Clin Res; 1981 Feb; 13(1):6-10. PubMed ID: 7018363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiclinic evaluation of timolol in the treatment of mild-to-moderate essential hypertension.
    Rofman BA; Kulaga SF; Gabriel MA; Thiyagarajan B; Nancarrow JF; Abrams WB
    Hypertension; 1980; 2(5):643-8. PubMed ID: 6998870
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension.
    Kanno M; Araie M; Masuda K; Takase M; Kitazawa Y; Shiose Y; Azuma I; Ogawa N; Ohdo S
    Arzneimittelforschung; 2006; 56(11):729-34. PubMed ID: 17220049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of nadolol in treatment of hypertension.
    Volicer L; Liang CS; Gavras H; Tifft CP; Kershaw GR; Gavras I; Griffith DL; Vukovitch R; Brunner HR
    J Clin Pharmacol; 1979; 19(2-3):137-47. PubMed ID: 33998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose response studies of bevantolol in hypertensive patients.
    Okawa KK
    Angiology; 1986 Mar; 37(3 Pt 2):233-8. PubMed ID: 2871783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Timolol and bendrofluazide in the management of hypertension in general practice.
    Wheatley D
    Eur J Clin Pharmacol; 1978 Dec; 14(5):319-24. PubMed ID: 365544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.